Our approach

PARKS platform predicting signatures that define condition

Our platform applies high-end mass spectrometry to measure disease-defining signatures from blood cells. By combining high-accuracy mass spectrometry measurements with machine learning, we have identified panels of proteins that identify Parkinson’s from subjects with atypical parkinsonism, or from healthy individuals. Our current signatures derive from patients and healthy donors in Southwestern Finland. Further validation in US and European cohorts is underway. Please contact us if you have samples for testing.